14.25
+0.04(+0.28%)
Currency In USD
Address
3675 Market Street
Philadelphia, PA 19104
United States of America
Phone
215 921 7600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
499
First IPO Date
May 31, 2007
| Name | Title | Pay | Year Born |
| Bradley L. Campbell | Chief Executive Officer, President & Director | 1.43M | 1976 |
| David Clark | Chief People Officer | 791,106 | 1975 |
| Jeffrey Castelli | Chief Development Officer | 795,135 | 1972 |
| Simon Nicolas Reade Harford | Chief Financial Officer | 801,304 | 1960 |
| Ellen S. Rosenberg | Chief Legal Officer & Corporate Secretary | 887,784 | 1963 |
| Jill Weimer | Chief Science Officer | 0 | N/A |
| Andrew Faughnan | Vice President of Investor Relations | 0 | N/A |
| Patrik S. Florencio | Global Chief Compliance & Risk Officer | 0 | N/A |
| Diana Moore | Head of Global Corporate Communications | 0 | N/A |
| Samantha Prout | Chief Accounting Officer & Controller | 0 | 1978 |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.